2021-11-16-世界卫生组织-Cervical_cancer_Kyrgyzstan_2021_country_profile_1页_64kb

Kyrgyzstan Cervical Cancer Profile Summary

Morbidity and Mortality

• Crude cervical cancer incidence: 15.1 per 100,000 women in 2020.
• Age-standardized incidence: 15.4 per 100,000 women in 2020.
• Cumulative risk: 1.6% by age 74 in 2020.
• Cervical cancer deaths: 13,700 in 2019.
• Mortality-to-incidence ratio: 0.57 in 2020.
• Cancer registry: Existed in 2021.
• Related risk factors: Low tobacco use prevalence (0.09% women aged 15+ in 2020), outdated condom use data (2012), and HIV incidence low.

Primary Prevention

• HPV vaccination: Not included in national routine schedule (as of 2021).
• Vaccination program coverage among girls: First dose 3%, final dose 67% in 2020.
• Program status: Introduced in 2020, coverage varies, target population girls.
• Scale: Not detailed, coverage indicated.
• Risk factors: Covered (e.g., low tobacco use).

Secondary Prevention

• National screening program: Does not exist as of 2021.
• Primary screening test used: Not specified, but 40% of women aged 30-49 have been ever screened, 33% screened in last 5 years.
• Target age range: Not clearly defined for a national program.
• Early detection strengthening: Programmes exist in primary health care for symptom detection.
• Referral system: Clearly defined from primary to secondary/tertiary care in place.

Treatment and Supportive Care

• National guidelines exist: Yes, as of 2021.
• Cancer facilities and staffing: Radiotherapy, brachytherapy, and other specialist units provided, staff per 10,000 patients or listed years.
• Palliative care: Generally available in public health system for non-communicable diseases.
• Cancer diagnosis and treatment services: Basic services available.

WHO Elimination Strategy and Additional Details

• WHO targets for 2030: Cervical cancer elimination efforts ongoing.
• Population data: Total female population 3,242,000 in 2019, deaths 13,700 in 2019.
• HPV/Screening stats: 67% of girls vaccinated final dose by 2020, but only 3% first dose coverage. Vaccination not routinely included. Screening limited.